License agreement centered around development of a single ADC program Usage of Synaffix GlycoConnect®, HydraSpace® and toxSYN® ADC technologies to enhance efficacy, tolerability and target engagement ...

All right. Good afternoon, everyone. My name is Frank Tang and I'm with the investment banking division at Morgan Stanley. Before we get started, I'd like to read a quick disclaimer. For important ...

CLEVELAND, Ohio (WOIO/WUAB) - WUAB Cleveland’s 43 will switch from The CW Network to MyNetworkTV on Sept. 1. The affiliation change means all new programming for you, including Cleveland’s only news ...

As the maker of Veozah, which treats menopause-related vasomotor symptoms, Astellas Pharma has a vested interest in breaking down the societal stigma that may stop women from seeking care for their ...

Eli Lilly has agreed a deal to acquire French antibody-drug conjugate (ADC) specialist Mablink, continuing a series of transactions that build its position in what has become one of the ...

India’s CDMO sector surges with leading global outsourcing growth. Indian Contract Development and Manufacturing Organizations (CDMOs) are rising to the helm of the pharmaceutical sector, capitalizing ...

Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven clinical -stage oncology company developing targeted therapies for cancer that are being advanced using its proprietary computational biology and ...

DALLAS, September 03, 2025--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven clinical -stage oncology company developing targeted therapies for cancer that are being advanced using ...

Good afternoon, everyone. Thank you for joining us today. My name is Jack Lin, I'm the China biotech analyst for Morgan Stanley. And today, it's our pleasure to invite Zai Lab to join us in this ...

MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-stage small ...